David Oxley has joined BIORCHESTRA as Chief Business Officer, leading corporate strategy and steering global partnerships and capital market activities outside Korea. With extensive experience in developing corporate strategies, managing complex licensing transactions, and handling global operations, Mr. Oxley specializes in RNA encapsulation strategies targeting brain and CNS diseases like Alzheimer's, ALS, and Parkinson's. His background is marked by significant achievements, including orchestrating business strategies for Hong Kong listings, pioneering product launches, and directing global sales with comprehensive profit and loss responsibility. He excels in cross-border licensing and has played a crucial role in building effective global sales and marketing teams to achieve strategic goals. Mr. Oxley's diverse experience extends to serving on the boards of a medical device company and a children's foundation, as well as contributing to the Global Fund's private sector delegation combating infectious diseases in Africa. He holds a bachelor's degree from Portland State University and a master's in government and public health from Johns Hopkins University.